Commentary |

Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical Practice

Kathryn A. Phillips, PhD
JAMA. 2008;300(21):2542-2544. doi:10.1001/jama.2008.754.
Text Size: A A A
Published online


New testing technologies—increasingly based on genomic information—are essential in the shift toward personalized medicine and molecular targeted therapies. Considering the rapid proliferation of new tests, health care insurers and policy makers are interested in assessing evidence about their use and value.

It is critical to build an evidence base to support effective decision making related to testing technologies as they are used in clinical practice. The example of human epidermal growth factor receptor 2 (HER2, or ERBB2) testing for breast cancer illustrates the challenges and opportunities. Many groups, including the Institute of Medicine, Agency for Healthcare Research and Quality, Secretary's Advisory Committee on Genetics, Health, and Society, President's Council of Advisors on Science and Technology, and Evaluation of Genomic Applications in Practice and Prevention Project, have cited the need to improve the evidence base for genomic and testing technologies. This Commentary extends previous work, emphasizing the need for evidence to assess how technologies are actually used in clinical practice.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 18

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics